Motley Fool Asset Management LLC Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Motley Fool Asset Management LLC decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,123 shares of the biotechnology company’s stock after selling 1,238 shares during the quarter. Motley Fool Asset Management LLC’s holdings in BioMarin Pharmaceutical were worth $4,254,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. KB Financial Partners LLC boosted its stake in shares of BioMarin Pharmaceutical by 51.3% during the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Castleview Partners LLC purchased a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth about $35,000. Lindbrook Capital LLC raised its holdings in shares of BioMarin Pharmaceutical by 259.8% in the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 278 shares during the period. Allworth Financial LP raised its holdings in shares of BioMarin Pharmaceutical by 54.9% in the 4th quarter. Allworth Financial LP now owns 604 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 214 shares during the period. Finally, Signaturefd LLC raised its holdings in shares of BioMarin Pharmaceutical by 17.9% in the 3rd quarter. Signaturefd LLC now owns 1,283 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 195 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN traded down $9.03 during mid-day trading on Thursday, hitting $82.17. The stock had a trading volume of 7,884,446 shares, compared to its average volume of 1,437,064. The company has a market cap of $15.51 billion, a PE ratio of 93.38, a PEG ratio of 1.70 and a beta of 0.31. The company’s fifty day simple moving average is $87.74 and its two-hundred day simple moving average is $89.18. The company has a quick ratio of 1.57, a current ratio of 2.51 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a fifty-two week low of $76.02 and a fifty-two week high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The business had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. During the same quarter in the previous year, the firm posted $0.11 EPS. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. On average, equities analysts expect that BioMarin Pharmaceutical Inc. will post 1.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BMRN. Cantor Fitzgerald reiterated an “overweight” rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday. Wells Fargo & Company raised their target price on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday. Canaccord Genuity Group reiterated a “hold” rating and set a $91.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Scotiabank raised their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a report on Thursday. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.89.

Insider Activity at BioMarin Pharmaceutical

In related news, insider Henry J. Fuchs sold 35,341 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the transaction, the insider now owns 212,117 shares in the company, valued at approximately $18,068,126.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now owns 212,117 shares of the company’s stock, valued at approximately $18,068,126.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction on Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the sale, the director now directly owns 474,994 shares in the company, valued at approximately $43,347,952.44. The disclosure for this sale can be found here. Insiders sold 103,229 shares of company stock worth $9,062,967 in the last 90 days. 1.84% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.